Shilpa Medicare

Price chart

Previous close

₹953.65

Open

₹950.40

Day high

₹977.00

Day low

₹931.00

Listed on NSE since 3 December 2009.

Market value

₹18,652 Cr

P/E (trailing)

55.83

EPS (trailing)

₹17.08

Price to book

6.76

Dividend yield

0.06%

Return on equity

12.8%

Debt to equity

0.24

Profit margin

18.0%

Volume today

4.16 L

Average volume

11.45 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Shilpa Medicare’s results filed with NSE, consolidated (the whole group). Net profit is the share of Shilpa Medicare’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Shilpa Medicare’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Raichur

Employees

1,241

Company website · Profile: Yahoo Finance

No headlines name Shilpa Medicare in the last day or two.

• Dividend - Re 0.60 Per Share

  Dividend · ex-date 4 September 2026

• Bonus 1:1

  Bonu · ex-date 3 October 2025

• Dividend - Re 1 Per Share

  Dividend · ex-date 17 September 2025

• Annual General Meeting

  Action · ex-date 6 September 2024

• Annual General Meeting

  Action · ex-date 22 September 2023

• Annual General Meeting/Dividend - Rs 1.10 Per Share

  Dividend · ex-date 19 September 2022

• Dividend - Rs 1.10 Per Share

  Dividend · ex-date 20 September 2021 · record date 21 September 2021

• Annual General Meeting

  Action · ex-date 20 September 2021

Source: NSE. Latest first, 8 of 20.